Pluri Inc (PLUR)
Pluri Inc. is a biotechnology company focused on research, development, and manufacturing of cell-based products, cell therapeutics, and related technologies. Its pipeline includes placenta-derived cell therapy candidates aimed at inflammatory conditions, muscle injuries, and hematologic disorders, along with an immunotherapy platform. Key programs include PLX-PAD, which is being studied for indications such as acute muscle injury after hip fracture, acute respiratory distress syndrome related to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia, and PLX-R18, a placenta-derived cell therapy under development for hematopoietic complications and in Phase I testing for hematopoietic cell transplantation. The company also works on an allogeneic MAIT cell therapy platform, offers cell manufacturing services and cell-based coffee, and develops cultivated meat products. Its activities span regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. Pluri has a collaboration with Bar-Ilan University on cancer immunotherapy for solid tumors, and it is based in Haifa, Israel.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PLUR
|
$1.50
|
38.8% Upside
|
Undervalued
|
$12 1,011.1% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
13.1x
|
13.332 M
|
46.044 M
|
64.8%
|
48.6%
|
-93.7
|
84.9%
|
